Overview

This collection of cutting-edge reviews comprehensively examines the current status of novel antifolates, an important class of anticancer drugs. The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate, other dihydrofolate reductase inhibitors, 5-fluorouracil, and the new generation of antifolates - the thymidylate synthase and glycinamide ribonucleotide formyltransferase inhibitors. In addition, they review in depth the modulation of antifolate drugs, folate and antifolate transport mechanisms, polyglutamation, resistance, and drug combinations, as well as pharmacogenomics, pharmacodynamics, regulation of gene expression, and mechanisms of cell death. Antifolate Drugs in Cancer Therapy provides entre to exciting new avenues for future research and constitutes a new standard reference for all basic scientists and clinicians engaged in cancer therapeutics.

Full Product Details

Author:   Ann L. Jackman
Publisher:   Humana Press Inc.
Imprint:   Humana Press Inc.
Edition:   1999 ed.
Dimensions:   Width: 17.80cm , Height: 2.50cm , Length: 25.40cm
Weight:   1.078kg
ISBN:  

9780896035966

ISBN 10:   0896035964
Pages:   456
Publication Date:   22 January 1999
Audience:   College/higher education ,  Professional and scholarly ,  Undergraduate ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Out of stock  
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Table of Contents

1 Antifolate Drugs: Past and Future Perspectives.- 2 Folate Biochemistry in Relation to Antifolate Selectivity.- 3 Clinical Pharmacology and Resistance to Dihydrofolate Reductase Inhibitors.- 4 Development of Nonpolyglutamatable DHFR Inhibitors.- 5 Fluoropyrimidines as Antifolate Drugs.- 6 Raltitrexed (Tomudextm), a Highly Polyglutamatable Antifolate Thymidylate Synthase Inhibitor: Design and Preclinical Activity.- 7 Tomudex: Clinical Development.- 8 Preclinical Pharmacology Studies and the Clinical Development of a Novel Multitargeted Antifolate, MTA (LY231514).- 9 GW1843: A Potent, Noncompetitive Thymidylate Synthase Inhibitor—Preclinical and Preliminary Clinical Studies.- 10 Preclinical and Clinical Studies with the Novel Thymidylate Synthase Inhibitor Nolatrexed Dihydrochloride (Thymitaqtm, AG337).- 11 ZD9331: Preclinical and Clinical Studies.- 12 Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors Lometrexol and LY309887.- 13 AG2034: A GARFT Inhibitor with Selective Cytotoxicity to Cells that Lack a G1 Checkpoint.- 14 Receptor- and Carrier-Mediated Transport Systems for Folates and Antifolates: Exploitation for Folate-Based Chemotherapy and Immunotherapy.- 15 Folates as Chemotherapeutic Modulators.- 16 Antifolate Polyglutamylation in Preclinical and Clinical Antifolate Resistance.- 17 Antifolates in Combination Therapy.- 18 Pharmacodynamic Measurements and Predictors of Response to Thymidylate Synthase Inhibitors.- 19 Molecular Regulation of Expression of Thymidylate Synthase.- 20 The Role of Uracil Misincorporation in Thymineless Death.- 21 Thymineless Death.- 22 Genetic Determinants of Cell Death and Toxicity.

Reviews

Author Information

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions